<DOC>
	<DOC>NCT00189683</DOC>
	<brief_summary>To compare maintenance chemotherapy with Xeloda to control after best response with first line chemotherapy in advanced colorectal cancer. Main endpoint is progression free survival. A total of 300 patients will be included.</brief_summary>
	<brief_title>Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patients with metastatic colorectal cancer (confirmed histologically) with objective response or stabilization after at least 6 cycles of first line chemotherapy (treatment of choice is selected freely by the investigator according to the recommendations and consensus in force), The interval between completion of first line chemotherapy and randomization should not exceed 4 weeks Age&gt;18 years ECOG status 0 to 2 Biological criteria prior to any chemotherapy: Neutrophils&gt;1.5 109 g/l, platelets&gt;100 109/l, haemoglobin&gt;10 g/dl, Creatininaemia&lt;150 ÔÅ≠mol/l, bilirubinaemia&lt;2x normal level Signed informed consent Life expectancy &gt; 3 months Metastatic colorectal cancer treated with more than one modality of first line chemotherapy (including oral fluoropyrimidines) Tumour progression after first line chemotherapy or before randomization Other tumour pathology Symptomatic cerebral metastases Any severe uncontrolled disease in addition to colorectal cancer (in particular decompensated cardiac failure (LVEF&lt;50%) or coronary insufficiency) Lack of integrity of the upper GI tract: malabsorption syndrome or major surgery of the stomach or the small intestine Severe renal impairment (creatinine clearance &lt; 30 ml/min) Severe psychiatric disorder (other than controlled depressive syndrome) Patient participating in another experiment Pregnant women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>